Advertisement
U.S. Markets closed

Nxera Pharma Co., Ltd. (SOLTF)

OTC Markets OTCPK - OTC Markets OTCPK Delayed Price. Currency in USD
7.130.00 (0.00%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.00
Open7.00
Bid7.61 x 40000
Ask8.59 x 40000
Day's Range7.00 - 7.00
52 Week Range7.00 - 13.43
Volume1,000
Avg. Volume64
Market Cap721.573M
Beta (5Y Monthly)0.65
PE Ratio (TTM)N/A
EPS (TTM)-0.77
Earnings DateNov 01, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateMar 27, 2015
1y Target EstN/A
  • GlobeNewswire

    Nxera Pharma to Host R&D Day 2024

    Nxera Pharma Co., Ltd. will hold an R&D Day on 6 November 2024 at 16:30 JST. The meeting will be held virtually via Zoom webinar. Please click here to pre-register for the event. Date: Wednesday, 6 November 2024 Time: 16:30 – 18:00 JST (7:30 – 9:00 GMT) Presenters: Chris Cargill, President and CEO Dr. Matt Barnes, Executive Officer, President of Nxera Pharma UK and Head of R&DDr. Makoto Sugita, Executive Officer, Chief Medical Officer (CMO) and President of Nxera Pharma JapanHironoshin Nomura, E

  • GlobeNewswire

    Nxera Pharma Appoints Experienced Commercial R&D Executive Makoto Sugita as Chief Medical Officer and President of Nxera Pharma Japan

    Dr. Sugita – formerly Vice President, Head of R&D for Bristol Myers Squibb in Japan – brings nearly 20 years’ experience in R&D and commercial roles working within the Japanese businesses of global pharmaceutical companies Tokyo, Japan and Cambridge, UK, 1 October 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – today announces the appointment of Dr. Makoto Sugita, M.D., Ph.D., MBA, as President of Nxera Pharma Japan, and Exec